Researchers developed a novel test that detects gluten immunogenic peptides in urine, the levels of which were found to correlate with mucosal damage in patients with celiac disease, according to data presented at UEG Week 2015.
“There is no test to measure gluten consumption in the U.S., and it is really hard for patients to avoid gluten; this leads to contamination and complications in celiac disease,” Francisco León, MD, PhD, CEO and chief medical officer of Celimmune and adjunct professor of medicine at Jefferson Medical College in Philadelphia, told Healio Gastroenterology. This “is the second method developed to measure gluten in Europe, after the gluten stool test ELISA developed by the same diagnostics company in Spain (Biomedal). This urine test is a lateral flow test with a couple of very sensitive antibodies discovered by Biomedal (G12 and A1) which recognize gluten immunogenic peptides (GIPs) after they have gone through the circulation and are excreted in the urine.”
In a clinical trial, León and colleagues collected urine samples from 76 healthy individuals and 58 patients with celiac disease, and tested the samples for gluten immunogenic peptides using this method. Samples were collected at different time points during which participants were subjected to different dietary conditions.
“The results were quite striking,” León said. “About half of the celiac patients on a gluten-free diet studied had detectable amounts of gluten in their urine. Secondly, there was a very good correlation between the presence of these levels of urinary gluten and mucosal damage.”
You can access complete information by clicking here (Healio Gastroenterology)